Safe, effective and consumer acceptable pharmaceutical products are highly sought-after solutions for dermatological concerns. Helix BioMedix innovation continues to bring the best in new drug candidates for these dermatological conditions and life-saving intervention for serious infections.
Acne is a common problem in adolescents and young adults. The disorder is caused by abnormal desquamation of follicular epithelium that results in obstruction of the pilosebaceous canal. This obstruction leads to the formation of comedones, which can become inflamed because of overgrowth of P.acnes. Such inflammation is caused by a number of elements including, the formation of free fatty acids from the breakdown of triglycerides by P.acnes, the pro-inflammatory surface components of P.acnes and the pro-inflammatory surface components of P.acnes released when the bacterium is killed.
There is an ever-increasing global problem of antimicrobial resistance.
This phenomenon has been well documented by the Centers for Disease Control
and Prevention, which recently identified a 28.5% increase in S. aureus
oxacillin (methicillin) resistance in hospitals taking part in the National
Nosocomial Infections Surveillance system from 1992-2003. Their report
concludes that action is necessary to control the spread of this organism,
and, to this end, several European countries have been successful in
identifying and treating colonized patients quickly. The ability of lipohexapeptides
to safely and effectively kill S. aureus in an abraded skin infection
model, and the fact that this class of molecule exhibits potent activity
against both methicillin and mupirocin (current therapy) resistant strains,
support its development potential. The broad spectrum of activity exhibited
by lipohexapeptides also enables possible application to chronic wounds,
burn wounds, and trauma wounds in which multiple pathogens can cause
significant morbidity and mortality. The market for such topical anti-infectives
is currently estimated to be $1.5 billion per year.